- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05928078
A Home-based e-Health Intervention in the Elderly: MOVI-ageing (MOVI-ageing)
A Home-based e-Health Intervention of Demanding Cognitive Exercise for the Improvement of Cardiorespiratory Fitness and Cognitive Function in the Elderly: MOVI-ageing.
This protocol study aims to evaluate the efficacy of the MOVI-ageing intervention, a complex home-based eHealth intervention of cognitive-demanding exercise for the elderly, in improving: global cognitive function and basic cognitive functions and cardiorespiratory and muscular fitness.
In addition, this sudy aims to evaluate the efficacy of the MOVI-ageing intervention, in improving: body composition (waist circumference and fat percentage), blood pressure, and health-related quality of life.
The MOVI-ageing project has been designed in three phases comprising: i) a tool development study; ii) a 12-week randomized efficacy/feasibility trial of the intervention; and iii), a large-scale implementation phase with a 12-week randomized trial.
The investigators will use a qualitative approach to improve the plataform design with the users perspective. Participants will have access to a platform where participants will be able to view videos of cognitively demanding physical exercise programs.
The videos will be directed by an avatar and the research staff will be able to know the degree of compliance with the program and the correct execution of the program through the use of Physio Galenus technology. The platform will have information on how to be more active, and chat lines to communicate with the research group. Participants will receive feedback on their compliance with the routines and reinforcement messages.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be carried out in three phases. During the first phase, the research team will conduct a literature review and focus groups to implement in the development of the online platform the information available in the scientific evidence and the needs and expectations of the people who will use it.
The second phase will include the implementation of the platform and its piloting in a small sample of the population. This second phase will allow the researchers to improve the platform and its access based on the results and user experiences. During the third phase the platform will be made accessible to a larger population group to show its effect on improving cognitive function and cardiorespiratory fitness in the elderly
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Celia Alvarez-Bueno, PhD
- Phone Number: +34625729642
- Email: celia.alvarezbueno@uclm.es
Study Contact Backup
- Name: Ivan Cavero-Redondo, PhD
- Phone Number: +34675568830
- Email: Ivan.Cavero@uclm.es
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- are 60 years of age or older of both genders;
- are retired regardless of the reason for retirement;
- do not meet frailty criteria according to Fried criteria;
- without disabilities for activities of daily living;
- living independently;
- without cognitive impairment as determined by the Mini-Mental test greater than 24 (considering the degree of schooling of the participants);
- able to walk at least 20 meters with or without walking aids.
Exclusion Criteria:
- mobility problem;
- serious health problem (e.g., recent myocardial infarction, recent heart attack, etc.). recent myocardial infarction, uncontrolled diabetes or uncontrolled hypertension);
- orthopedic or neurological disease that prevents training;
- Alzheimer's disease or dementia;
- progressive or terminal terminal illness;
- acute or chronic illness;
- history of heart attack;
- history of vertigo or recent head injury;
- health problems that may affect the ability to perform the EF programs (e.g. acute and painful joint inflammation, impaired mobility after a stroke), or any unstable health condition;
- use of medications that act at the neuron level (e.g., psychotropic medications);
- signs of incipient depression;
- pathology that makes it difficult to use the computer application through which the FE program will be developed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Participants will develop their usual activity
|
|
Experimental: Intervention
Participants will use the e-Health platform
|
Participants will be required to use the MOVI-ageing platform 3 times a week for 12 weeks.
The platform will include videos of cognitively demanding physical activities designed and guided by health professionals, who will also be able to check compliance with the intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive decline
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Using the Minimental State Examination (MMSE) for global function
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in cardiorespiratory fitness
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
6 minutes walking test (6MWT)
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Health-related quality of life
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
SF-12 test
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Depression, anxiety and stress
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Yesavage's 15-item GDS questionnaire
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Psychological well-being
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Scale proposed by Ryff and translated and validated in Spanish by Diaz et al
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Physical activity
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Axivity 6axes accelerometers (Axivity LTd. ) for seven consecutive days
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in Physical function
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Short Portable Physical Battery scale
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Concern about falls
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Falls Efficacy Scale International (FES-I)
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Weight
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
the mean of two measurements (using a scale (Seca® 861) with the participant barefoot and lightly clothed.
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Height
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
the mean of two measurements with a wall-mounted stadiometer (Seca® 222), with the participant barefoot and in an upright position while the sagittal midline of the back touches the vertical bar.
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Body mass index (BMI)
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
as weight (kg)/height2 (m2).
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Waist circumference
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
the mean of three measurements using a flexible tape measure at the midpoint between the last rib and the iliac crest at the end of a normal exhalation.
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Body fat percentage
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
the mean of two measurements using an eight-electrode Tanita® Segmental-418 bioimpedance system (Tanita Corp. Tokyo, Japan). |
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Body composition by densitometry
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
With the DXA
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in HbA1c
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
using the ADAMS A1c HA-8180V analyzer (Menarini Diagnostics®), a method certified by the NGSP (National Glycohemoglobin Standardization Program) and the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine).
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in Pulse wave velocity
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in Fasting plasma glucose, apolipoproteins A1 and B, insulin ultrasensitive protein C and endothelial glycocalyx (syndecan-1, syndecan-4 and heparan sulfate proteins)
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the Abbott® Cobas 8000 Roche Diagnostics® system.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in Endothelial function
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the ENDO-PAT.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in 24-hour blood pressure
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the MAPA Mobil-O-graph.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in Educational level
Time Frame: At baseline of the 12 weeks intervention in the 2nd phase
|
measured as the maximum level of education attained by each participant, classifying them as: cannot read or write, no studies, incomplete primary studies, primary studies, school graduate studies, higher baccalaureate studies, medium university studies, or higher university studies.
|
At baseline of the 12 weeks intervention in the 2nd phase
|
Change in Adherence to the Mediterranean diet
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
with the Mediterranean Diet Adherence Screener (MEDAS) questionnaire
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Sleep habits and quality of sleep
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
with the Pittsburgh Sleep Quality Index (PSQI)
|
Baseline and at the end of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Comorbidities
Time Frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
with the Charlson comorbidity index.
|
At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Attention
Time Frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Using the Flanker Task test
|
At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Working memory
Time Frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Using the AWMA (Automated Working Memory Assessment) test
|
At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in Cognitive flexibility
Time Frame: At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Using the DCCS (Dimension Change Card Sort) test
|
At baseline of the 12 weeks intervention in the 2nd and 3rd phase
|
Change in radial augmentation rate (rAIx)
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Change in central augmentation rate (cAIx)
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the SphygmoCor system (AtCor Medical Pty Ltd Head Office, West Ryde, Australia).
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
apolipoproteins A1 and B
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the Abbott® Cobas 8000 Roche Diagnostics® system.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
insulin ultrasensitive protein C
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the Abbott® Cobas 8000 Roche Diagnostics® system.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
endothelial glycocalyx (syndecan-1, syndecan-4 and heparan sulfate proteins)
Time Frame: Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
with the Abbott® Cobas 8000 Roche Diagnostics® system.
|
Baseline and at the end of the 12 weeks intervention in the 2nd phase
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI22/00878 PI22/00878
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Decline
-
Jean-François DémonetUniversity of Lausanne HospitalsActive, not recruitingCognitive Performance | Functional Capacity | Subjective Cognitive Decline | Age-related Cognitive DeclineSwitzerland
-
Rotman Research Institute at BaycrestSunnybrook Health Sciences Centre; University of Waterloo; Toronto Rehabilitation... and other collaboratorsTerminatedSubjective Cognitive Decline | Age-Related Cognitive DeclineCanada
-
National Taiwan University HospitalNational Taiwan Science Education Center(NTSEC)RecruitingCognitive Training | Subjective Cognitive DeclineTaiwan
-
Sahmyook UniversityCompletedCognition Disorders in Old Age | Subjective Memory Decline | Cognitive Decline, MildKorea, Republic of
-
University of Milano BicoccaRecruitingMild Cognitive Impairment | Subjective Cognitive DeclineItaly
-
Beijing Hospital of Traditional Chinese MedicineUnknownSubjective Cognitive Decline | Subjective Cognitive ComplaintChina
-
BaycrestCompletedSubjective Cognitive DeclineCanada
-
Evidation HealthNeurotrackCompleted
-
Fundacion Clinic per a la Recerca BiomédicaUnknownSubjective Cognitive Decline
-
Vanderbilt University Medical CenterRecruiting
Clinical Trials on intervention
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed
-
Vanderbilt UniversityAgency for Healthcare Research and Quality (AHRQ)Completed